Suspected Aripiprazole-induced neutropenia in a geriatric patient: a case report

Abstract

Background: Aripiprazole, a third-generation antipsychotic medication, has been used to treat a range of psychiatric disorders. According to the U.S. Food and Drug Administration's prescribing information, the most common adverse reactions in adult patients in clinical trials (≥10%) were nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, and insomnia. While hematological adverse effects may occur with aripiprazole, there is very limited information in the published literature on such adverse outcomes. Case presentation: A 68-year-old Caucasian male with treatment resistant depression was hospitalized for suicidal ideation. The patient developed neutropenia after aripiprazole was introduced as an augmentation agent. The neutropenia was reversible with discontinuation of the medication. Conclusions: To our knowledge, we describe the first case report of suspected neutropenia-induced by aripiprazole use in a geriatric patient. While hematological adverse reactions are rare, we recommend adding CBC to the standard adverse systemic reaction monitoring of antipsychotic medications, particularly among the elderly.

Clozapine and aripiprazole‐induced neutropenia

“…In addition there have been cases of aripiprazole‐induced neutropenia subsequent to other antipsychotic‐induced neutropenia documented in the literature 15,16 . Previous reports on aripiprazole‐related neutropenia have indicated that blood levels of WBC and ANC demonstrated a rise within three to four days after discontinuing aripiprazole and that baseline levels were achieved within one week 17 . This is consistent with the patient described as levels of WBC and ANC returned to baseline after nine days showing a temporal relationship with the cessation of aripiprazole.…”

Mibefradil inhibits the proliferation of triple-negative breast cancer by targeting AURKA to regulate apoptosis signal pathway

“…Then, to explore unproved anti-tumor indications for non-oncologic therapeutic drugs, 8 non-oncologic therapeutic drugs were focused on the further screening (Table 1). After excluding amlodipine and simvastatin, which had been proved to have anti-tumor effects on TNBC [31][32][33][34],and removing aripiprazole with serious side effects [35], Mibefradil was finally screened out for the following antitumor effect investigation in TNBC.…”